Pasotuxizumab
- Product NamePasotuxizumab
- CAS1442657-12-6
- CBNumberCB58080908
- MW0
- MOL FileMol file
- MSDS FileSDS
Pasotuxizumab Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| ChemScene CS-0633952 | 1mg | $487 | Pasotuxizumab 99.79% |
Buy |
| ChemScene CS-0633952 | 5mg | $1267 | Pasotuxizumab 99.79% |
Buy |
| ChemScene CS-0633952 | 10mg | $2026 | Pasotuxizumab 99.79% |
Buy |
| aablocks AA02ANZE | 1mg | $535 | Pasotuxizumab >98% |
Buy |
| aablocks AA02ANZE | 5mg | $1335 | Pasotuxizumab >98% |
Buy |
Pasotuxizumab Chemical Properties,Usage,Production
Uses
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2].in vivo
Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC50s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures[2].
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells[2].
| Animal Model: | PC-3-huPSMA mouse xenograft model[2] |
| Dosage: | 0.005-5 mg/kg |
| Administration: | i.v., once daily |
| Result: | Inhibited tumor growth by 86% (0.005 mg/kg/d) and 99% (5 mg/kg/d). |
| Animal Model: | BALB/c mice (PK Assay)[2] | |||||||||||||||
| Dosage: | 0.1, 0.3, and 1 mg/kg | |||||||||||||||
| Administration: | i.v. bolus administration or s.c. | |||||||||||||||
| Result: | Pharmacokinetic profile of Rafivirumab.
|
References
[1] Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034.[2] Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11(12):2664-73. DOI:10.1158/1535-7163.MCT-12-0042
Preparation Products And Raw materials
Pasotuxizumab Suppliers
Global(13)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 1-631-485-4226; 16314854226 |
info@bocsci.com | United States | 9920 | 65 | |
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 7996 | 62 | |
| 027-65317797 15926423062 |
422450190@qq.com | China | 10302 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 021-65675885 18964387627 |
customer_service@efebio.com | China | 11963 | 58 | |
| 15111215862 18229892877 |
3062105966@qq.com | China | 5571 | 58 | |
| 027-87008169 17762441161 |
info@atagenix.com | China | 9997 | 58 | |
| 021-10000000 13000000000 |
gzj@abmole.cn | China | 9323 | 58 |
1442657-12-6, PasotuxizumabRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine